Evolutionary trade-offs associated with loss of PmrB function in host-adapted Pseudomonas aeruginosa by Bricio-Moreno, L et al.
Evolutionary trade­offs associated with 
loss of PmrB function in host­adapted 
Pseudomonas aeruginosa
Bricio­Moreno, L, Sheridan, V, Goodhead, IB, Armstrong, S, Wong, JKL, Waters, 
EM, Sarsby, J, Panagioutou, S, Dunn, J, Chakraborty, A, Fang, Y, Griswold, KE, 
Winstanley, C, Fothergill, JL, Kadioglu, A and Neill, DR
http://dx.doi.org/10.1038/s41467­018­04996­x
Title Evolutionary trade­offs associated with loss of PmrB function in host­
adapted Pseudomonas aeruginosa
Authors Bricio­Moreno, L, Sheridan, V, Goodhead, IB, Armstrong, S, Wong, JKL, 
Waters, EM, Sarsby, J, Panagioutou, S, Dunn, J, Chakraborty, A, Fang, Y, 
Griswold, KE, Winstanley, C, Fothergill, JL, Kadioglu, A and Neill, DR
Type Article
URL This version is available at: http://usir.salford.ac.uk/id/eprint/47160/
Published Date 2018
USIR is a digital collection of the research output of the University of Salford. Where copyright 
permits, full text material held in the repository is made freely available online and can be read, 
downloaded and copied for non­commercial private study or research purposes. Please check the 
manuscript for any further copyright restrictions.
For more information, including our policy and submission procedure, please
contact the Repository Team at: usir@salford.ac.uk.
ARTICLE
Evolutionary trade-offs associated with loss of
PmrB function in host-adapted Pseudomonas
aeruginosa
Laura Bricio-Moreno1, Victoria H. Sheridan1, Ian Goodhead2, Stuart Armstrong1,3, Janet K.L. Wong1,
Elaine M. Waters1,6, Joscelyn Sarsby4, Stavros Panagiotou1, James Dunn1, Adrita Chakraborty1, Yongliang Fang5,
Karl E. Griswold 5, Craig Winstanley1, Joanne L. Fothergill1, Aras Kadioglu1 & Daniel R. Neill 1
Pseudomonas aeruginosa colonises the upper airway of cystic ﬁbrosis (CF) patients, providing
a reservoir of host-adapted genotypes that subsequently establish chronic lung infection. We
previously experimentally-evolved P. aeruginosa in a murine model of respiratory tract
infection and observed early-acquired mutations in pmrB, encoding the sensor kinase of a
two-component system that promoted establishment and persistence of infection. Here,
using proteomics, we show downregulation of proteins involved in LPS biosynthesis,
antimicrobial resistance and phenazine production in pmrB mutants, and upregulation of
proteins involved in adherence, lysozyme resistance and inhibition of the chloride ion channel
CFTR, relative to wild-type strain LESB65. Accordingly, pmrB mutants are susceptible to
antibiotic treatment but show enhanced adherence to airway epithelial cells, resistance to
lysozyme treatment, and downregulate host CFTR expression. We propose that P. aeruginosa
pmrB mutations in CF patients are subject to an evolutionary trade-off, leading to enhanced
colonisation potential, CFTR inhibition, and resistance to host defences, but also to increased
susceptibility to antibiotics.
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Pseudomonas aeruginosa lung infections are the singlebiggest cause of mortality in people with cystic ﬁbrosis(CF)1,2. Such infections are typically chronic, highly resis-
tant to antimicrobial therapy and punctuated by periodic
exacerbations. P. aeruginosa is ubiquitous in the environment and
will thrive under diverse conditions3. Such adaptability is
facilitated by a large and plastic genome4. However, we still know
relatively little about the early adaptation events that take place
within the host during infection.
Previous work by ourselves and others has suggested that the
upper airways (the paranasal sinuses and nasopharynx) may
function as a protected niche and “evolutionary nest” for
P. aeruginosa, allowing prolonged colonisation in an environment
with fewer immune defence agents and greater nutrient
availability than the lung5–8. Gradual adaptation to the host
environment paves the way for subsequent seeding into the lungs
and establishment of chronic infection. When P. aeruginosa was
cultured simultaneously from the sinuses and lungs of patients
who had undergone Endoscopic Sinus Surgery, isolates from the
two sites were genetically identical in 95% of patients8. Further-
more, P. aeruginosa form bioﬁlms in the sinuses without
triggering strong cellular inﬂammatory responses8.
We have previously used a chronic P. aeruginosa respiratory
infection model in mice to demonstrate that, whilst host immune
clearance mechanisms efﬁciently remove bacteria infecting the
lung, colonisation persists in the nasopharynx for long periods6.
The same study showed that prolonged colonisation is associated
with subsequent reseeding events, whereby P. aeruginosa reap-
pear in the lungs several weeks after initial immune clearance.
Genome sequencing of isolates taken from nasopharynx and
lungs one month post-infection revealed the presence of a single
nucleotide polymorphism (SNP) resulting in a missense mutation
in pmrB. This mutation was present in multiple isolates taken
from different mice6. We have since compared the PmrB amino
acid sequences of the Liverpool Epidemic Strain (LES)B65 used
for the initial infection (DDBJ sequence read archive ERS2269679
(http://ddbj.nig.ac.jp/DRASearch/sample?acc=ERS2269679)) and
PAO1 (GenBank AAG08163 (https://www.ncbi.nlm.nih.gov/
protein/AAG08163.1)) and observed no differences, suggesting
the SNP acquired by LESB65 in the mouse model was not a
reversion mutation. An isolate with this pmrB SNP showed a
greatly enhanced ability to colonise mouse lungs compared to
both the LESB65 used in the original infection and an isolate
taken from the mouse model that did not have a pmrB SNP
(referred to as pmrB WT hereafter)6. Thus, our previous study
suggested that acquisition of pmrB mutations early in infection
appeared to confer a selective advantage in the establishment of
lung infection. The Liverpool Epidemic Strain is a widely studied,
transmissible lineage of P. aeruginosa from CF patients9. Isolates
of this strain have been shown to have a modiﬁed LPS structure,
lacking an O-antigen9,10, similar to other clinical isolates. Here,
we describe the phenotypic changes associated with pmrB
mutation that enable efﬁcient lung colonisation.
Two-component regulatory systems are key regulators of
virulence in bacteria, allowing the expression of multiple genes to
be coupled to changes in the environment. P. aeruginosa has
multiple two-component systems, amongst which PhoPQ
and GacAS are probably the best characterised11. Phenotypic
changes in P. aeruginosa that characterise the switch from acute
to chronic infection are under the control of GacAS12,13. PmrAB
is another such two-component system, involved in the mod-
iﬁcation of LPS in P. aeruginosa, and mutations in the pmrAB
operon have been linked to resistance to cationic antimicrobial
peptides14.
The mouse infection model from which we previously isolated
P. aeruginosa pmrB SNP mutants did not include any antibiotic
treatment6 and so we hypothesised that the selective pressure for
mutation may come from host-derived antimicrobial peptides or
that the phenotype conferred by the SNP mutation might be dif-
ferent from those previously reported. This was the starting point
for the present study, wherein we describe a signiﬁcantly altered
phenotype of P. aeruginosa lacking pmrB or those carrying the
in vivo acquired pmrB SNP and demonstrate that these changes aid
in multiple facets of host colonisation by conferring resistance to
host antimicrobials, enhanced adherence to host surfaces and an
ability to modulate the local environment in a way that drives a CF
lung phenotype. Our ﬁndings highlight the key role played by the P.
aeruginosa PmrAB two-component regulatory system in regulating
a wide range of biological processes and virulence mechanisms.
Finally, we propose that the evolutionary trade-off associated with
pmrB mutation may offer opportunities for therapeutic interven-
tion, as enhanced in vivo ﬁtness is offset by increased susceptibility
to several classes of antibiotics.
Results
Loss-of-function pmrB mutations confer lysozyme resistance.
Neutrophils are a major defence against bacterial infection of the
respiratory tract and neutrophil degranulation releases anti-
microbial peptides and enzymes15. In order to determine the effect
of pmrB mutation on susceptibility to neutrophil killing, human
HL-60 neutrophils and mouse neutrophils isolated from bone
marrow were cultured with phorbol myrisate acetate (PMA) to
induce degranulation and culture supernatants (containing granule
contents) were transferred to LESB65, a pmrB deletion mutant on
the LESB65 background (ΔpmrB) or two LESB65-derived isolates
taken from 28 days post-infection in the mouse infection model,
one with and one without a pmrB SNP (referred to as pmrB SNP
and pmrB WT, respectively, hereafter, and as NP22_2 and NP22_4
in ref.6). A full description of the additional mutations in the
LESB65-derived isolates, determined by PacBio sequencing, can be
found in Supplementary Table 1. Isolates with mutated pmrB (pmrB
deletion and SNP mutants) showed signiﬁcantly enhanced
resistance to killing by neutrophil-conditioned media (Fig. 1a, b).
To determine whether resistance to a neutrophil-derived anti-
microbial accounted for this phenotype, the four bacterial isolates
were cultured with β-defensin 2, mCRAMP (the murine homologue
of the human cathelicidin LL-37) or lysozyme. The two pmrB
mutants showed signiﬁcantly enhanced resistance to lysozyme
killing (Fig. 1c), but not to β-defensin 2 or mCRAMP in two-way
ANOVA analysis (Supplementary Fig. 1A and B). Lysozyme is
abundant in the mammalian airway16 and is active against both
Gram-positive and Gram-negative species17,18. Signiﬁcant differ-
ences in resistance between isolates were observed at lysozyme
concentrations within the physiological range found in saliva19.
Lysozyme resistance obtained through pmrB mutation may,
therefore, provide a selective advantage in the establishment of
respiratory tract infection.
Antimicrobial susceptibility in pmrB mutants. Mutations in the
pmrAB system have previously been linked to changes in resistance
to antibiotics14,20. To determine whether the phenotypic changes in
pmrB mutants that conferred lysozyme resistance also inﬂuenced
resistance to antibiotics, minimum inhibitory concentration
(MIC) assays were performed (Table 1, Supplementary Fig. 2A-E).
Strikingly, isolates with pmrB mutations were notably more
susceptible to 6 of the 7 antibiotics tested, when antibiotic con-
centration required to inhibit 90% growth (MIC90) was determined
(Table 1). These antibiotics included tobramycin and colistin,
commonly used in the treatment of P. aeruginosa infections in
people with CF. Similarly, P. aeruginosa with a transposon insertion
in pmrB showed enhanced susceptibility to both tobramycin and
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colistin, relative to the parental PAO1 strain (Supplementary
Table 2). Thus, on both the LES and PAO1 background, loss of
pmrB function is associated with a relative increase in antibiotic
susceptibility. The evolution of resistance to lysozyme at the cost of
antibiotic susceptibility is an example of collateral sensitivity, as has
been previously described for P. aeruginosa pmrBmutants, in which
resistance to gentamicin was associated with penicillin sensitivity21.
Chronic P. aeruginosa lung infections are characterised by
bacterial growth in bioﬁlm that provides resistance to antibiotic
treatment and host immune responses22,23. Although differences in
tobramycin sensitivity between isolates were less pronounced when
grown in an artiﬁcial sputum model (ASM) of bioﬁlm growth, the
increased susceptibility of pmrB mutants relative to LESB65 was
evident at 4 and 8 µg/ml tobramycin (Supplementary Fig. 3A).
The effectiveness of lysozyme is also reduced in bioﬁlms and in
the chronically infected lung, due to electrostatic sequestration of
the enzyme by infection-associated anionic biopolymers24,25. This
was clear when LESB65 was grown in ASM, where it showed
complete resistance to lysozyme at all concentrations tested (data
not shown). However, when electrostatic sequestration by anionic
biopolymers in ASM was negated through use of charge-
engineered lysozyme24,26, the differential lysozyme resistance of
pmrB mutants could still be observed (Supplementary Fig. 3B).
This charge-engineering did not signiﬁcantly enhance lysozyme
killing of any of the four isolates when experiments were
performed in planktonic culture (Supplementary Fig. 4).
Proteomics analysis of pmrB mutants. The dichotomous phe-
notypic changes in pmrB mutants, with enhanced resistance to a
key host derived antimicrobial but increased susceptibility to
antibiotics, suggested that pmrB mutation might lead to sig-
niﬁcant changes in bacterial gene expression, protein production
or physiology. To explore this, we performed proteomic analysis
of LESB65 and ΔpmrB grown in liquid culture. We found 216
proteins with signiﬁcantly different abundance in LESB65 cul-
tures compared to ΔpmrB (Fig. 2, Supplementary Data 1 and
Supplementary Fig. 5), and these included the two proteins of the
PmrAB two-component regulatory system, as well as key viru-
lence factors (Table 2). Of the proteins identiﬁed as differentially
abundant between the two isolates, 60% (129/216) were enriched
in ΔpmrB.
Supportive of our phenotypic observations, several proteins with
described roles in antimicrobial resistance were signiﬁcantly more
abundant in LESB65 than in ΔpmrB. These included the protein
products of several genes of the arn locus, which is crucial to the
synthesis of the lipid A component of bacterial lipopolysaccharide
and which mediates resistance to cationic antimicrobials through
addition of 4-amino-L-arabinose to lipid A14. Expression of the arn
locus has been shown to be under the control of two-component
systems including PhoPQ and PmrAB14,27,28. Using MALDI-TOF
mass spectrometry, differences in lipid A traces were detected.
Peaks corresponding to both penta-acyl lipid A and hexa-acyl lipid
A were signiﬁcantly reduced in ΔpmrB compared to the isogenic
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Fig. 1 P. aeruginosa pmrB mutants are resistant to host defence molecules and lysozyme killing. Supernatants from phorbol 12-myristate 13-acetate (PMA)-
stimulated (a) HL-60 or (b) mouse bone marrow neutrophil cultures were transferred to mid-log growth P. aeruginosa. Colony forming units (CFU) as a
percentage of control. Control bacteria were exposed to supernatant from non-activated (no PMA) HL-60 cultures. c Optical density at 600 nm of
P. aeruginosa grown in the presence of lysozyme (mean ± s.d.). Results are expressed as a percentage of the no-lysozyme control for each isolate and are a
composite of 3 biological replicates per isolate, each containing 3 technical replicates. Asterisks (*) represent signiﬁcant differences in ANOVA performed on
CFU counts (a, b) or OD readings, with lysozyme as a covariant (c), with Dunnett’s multiple comparison test vs. LESB65. *p < 0.05, **p < 0.01, ***p < 0.005
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wild type LESB65 (Supplementary Fig. 6). Thus ΔpmrB, that
demonstrated reduced expression of proteins of the arn locus, may
also have reduced lipid A content.
Protein PA4775 (T224_RS56950 in LESB65), which was
enriched in LESB65 but not ΔpmrB has also been linked to
resistance to both antibiotics and oxidative damage via an LPS-
dependent mechanism29. Other proteins with roles in antimicro-
bial resistance that were more abundant in LESB65 include CprA,
which contributes to polymyxin resistance by an arn-independent
pathway30, and the multidrug efﬂux pump protein MexE31.
Proteins involved in phenazine biosynthesis were also enriched in
LESB65 as compared to ΔpmrB. Quantiﬁcation of pyocyanin in
cultures of LESB65, pmrB WT, pmrB SNP and ΔpmrB, conﬁrmed
that loss of PmrB function is associated with reduced pyocyanin
production (Supplementary Fig. 7). Pyocyanin is a key virulence
factor of P. aeruginosa, and it is unclear how its downregulation in
ΔpmrB might contribute to increased survival in vivo. Notably
however, pyocyanin is a stimulator of IL-8 release from the human
airway epithelium and reduced production may aid evasion of
neutrophil responses prior to establishment of bioﬁlm32,33.
Table 1 Antibiotic susceptibility of Psuedomonas aeruginosa isolates
Minimum inhibitory concentration (µg per ml) required for 50% or 90% growth inhibition. Median MIC50 and MIC90 from a minimum of 5 replicates (range 5–9) is in bold font, range is in brackets.
The two/three most sensitive isolates for each antibiotic are shaded grey
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The lysozyme resistance observed with ΔpmrB is likely a
consequence of increased production of the inhibitor of vertebrate
lysozyme (Ivy) protein, enriched 2.66-fold in ΔpmrB relative to
LESB65 (Table 2). An increase in cif expression was also detected
in ΔpmrB and pmrB SNP using qPCR (Supplementary Table 3).
Ivy is a proteinaceous inhibitor of lysozyme ﬁrst described in
Escherichia coli34. E. coli ivy knockout mutants exhibit growth
defects in lysozyme-rich environments, including hen egg white
and saliva35. However, Deckers et al. found no effect of ivy
deletion in P. aeruginosa PAO1 on growth in lysozyme-containing
saliva or egg white, perhaps due to compensatory lysozyme
resistance mechanisms such as that mediated by MliC36.
Modulation of CFTR by pmrB mutants. The cystic ﬁbrosis
transmembrane conductance regulator (CFTR) inhibitory protein
Cif was 5.65-fold more abundant in ΔpmrB than in LESB65
(Table 2). An increase in cif expression was also detected in
ΔpmrB and pmrB SNP using qPCR (Supplementary Table 3).
Cif inhibits endocytic recycling of CFTR in human epithelial
cells37, decreasing apical membrane expression of the protein38.
Furthermore, Cif is expressed in the CF lung38, suggesting that
P. aeruginosa can phenocopy the CF lung environment, poten-
tially facilitating colonisation and chronic infection. To determine
whether the high levels of Cif measured in ΔpmrB samples was
of functional relevance, LESB65 and ΔpmrB were cultured
with A549 human pulmonary epithelial cells and incubated
overnight before CFTR expression was assessed by ﬂow cyto-
metry. Strikingly, although A549 CFTR expression was unaffected
by co-culture with LESB65, signiﬁcantly decreased CFTR
expression was evident on A549 cells cultured with ΔpmrB
(Fig. 3a, b). Similarly, pmrB SNP, but not pmrB WT was able
to reduce CFTR expression on A549 cells (Fig. 3b) and the same
phenotypes were observed when Detroit human pharyngeal epi-
thelial cells were used (Fig. 3c). This raises the possibility that
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Fig. 2 Principal component biplot of LESB65 and ΔpmrB proteomics data
showing proteins with signiﬁcantly different abundance between samples.
Five biological replicates were performed for each isolate. Unit variance
scaling is applied to rows; SVD with imputation is used to calculate
principal components. X axis and Y axis show principal component 1 and
principal component 2 that explain 59.6% and 16.7% of the total variance,
respectively. Prediction ellipses are such that with probability 0.95, a
new observation from the same group will fall inside the ellipse. PCA
analysis of the full dataset, with all detected proteins, can be found in
Supplementary Fig. 4
Table 2 Differential protein abundance in LESB65 vs. ΔpmrB grown in liquid culture
Biological process Protein name Gene Fold
change
q-value
Type IV pili Type IV ﬁmbrial biogenesis protein PilV pilV PA4551 6.14 0.003560888
Type IV ﬁmbrial biogenesis protein PilY2 pilY2 PA4555 5.80 0.018144003
Pilus associated adhesin PilY1 pilY1 PA4554 2.33 0.026743646
CFTR inhibition CFTR inhibitory factor CIF cif PA2934 5.65 0.014178322
Lysozyme inhibition Inhibitor of vertebrate lysozyme ivy PA3902 2.66 0.049597254
Two-component
signalling
PmrB: two-component signal sensor kinase pmrB PA4777 −20.13 0.000337869
PmrA: two-component signal response regulator pmrA PA4776 −25.95 0.000615523
Phenazine biosynthesis Phenazine biosynthesis protein PhzD phzD1 phzD2 PA1902
PA4213
−5.37 0.001208844
Phenazine biosynthesis protein PhzE phzE1 phzE2 PA1903
PA4214
−3.93 0.001208844
Pyridoxal 5’-phosphate synthase phzG1 PA4216 −2.98 0.01260054
Phospho-2-dehydro-3-deoxyheptonate aldolase phzC1 phzC2 PA1901
PA4212
−6.89 0.000837624
RND multidrug efﬂux membrane fusion protein MexE* mexE PA2493 −5.39 0.029669765
Anthranilate--CoA ligase pqsA PA0996 −2.82 0.040457292
BfmS bfmS PA4102 −3.79 0.020754134
LPS modiﬁcation 4-deoxy-4-formamido-L-arabinose-phosphoundecaprenol deformylase
ArnD
arnD PA3555 −26.31 0.000200769
Bifunctional polymyxin resistance protein ArnA arnA PA3554 −18.63 0.000337869
Undecaprenyl phosphate-alpha-4-amino-4-deoxy-L-arabinose arabinosyl
transferase
arnT PA3556 −11.37 0.003786234
UDP-4-amino-4-deoxy-L-arabinose--oxoglutarate aminotransferase arnB PA3552 −7.17 0.01284628
3-deoxy-D-manno-octulosonic-acid (KDO) transferase waaA PA4988 −3.85 0.040439226
Antimicrobial
resistance
CprA cprA PA1559 −19.96 0.005901835
CprA cprA PA1560 −30.39 2.78965E-05
Uncharacterised protein PA4775 −22.89 0.00018425
Proteins dowregulated in ΔpmrB relative to LESB65 are denoted with a minus fold-change
*MexE is also involved in antibiotic resistance
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the success of pmrB mutants in vivo may reﬂect an ability to
modulate the host environment to create conditions conducive
to bacterial growth.
Loss of cif or ivy attenuates colonisation potential. To deter-
mine whether Ivy and Cif make contributions to P. aeruginosa
colonisation and survival in vivo, PAO1 transposon mutants with
insertions in ivy or cif were compared to the parental PAO1 strain
in a mouse inhalation infection model6. Lack of either Cif or
Ivy led to a signiﬁcant defect in establishment of infection that
was more pronounced in lung than nasopharynx (Fig. 4a, b).
Cif and Ivy mutant lung CFU were signiﬁcantly reduced vs.
PAO1 at days 1, 3 and 7 post-infection and infection was cleared
from lung in 5/6 Cif and Ivy-infected mice, but only 2/6 PAO1-
infected mice (Fig. 4a).
Enhanced airway adhesion and motility in pmrB mutants.
Several proteins involved in type IV pili biosynthesis were sig-
niﬁcantly more abundant in ΔpmrB than in LESB65. Type IV pili
play crucial roles in mediating adhesion to host surfaces and in
bacterial motility, but also in environmental sensing and viru-
lence39. To determine whether increased abundance of type IV
pili proteins in ΔpmrB enabled more efﬁcient adherence to
airway epithelial cells, adhesion/invasion assays were performed
with A549 human alveolar epithelial cells and Detroit human
pharyngeal epithelial cells (Fig. 5a, b). In all samples tested, less
than 15% of bacteria were found to have adhered to epithelial
cells after 2 h of co-culture, but the proportion of adhered
bacteria was signiﬁcantly higher in ΔpmrB-epithelial cell co-
cultures than in LESB65-epithelial cell cultures (Fig. 5a). Adher-
ence is key to persistence and establishment of bioﬁlms40, and
increased adherence in pmrB mutants may contribute to in vivo
virulence.
The proportion of invaded bacteria found to be residing
within A549 epithelial cells following triton X-induced lysis was
higher for LESB65 than for ΔpmrB (Fig. 5b, p= 0.07 in unpaired
t-test with Welch’s correction when considered as a percentage
of total CFU, p < 0.01 when considered as a percentage of
adhered CFU only). This may be a consequence of the CFTR
downregulation induced by ΔpmrB, as CFTR has been implicated
in P. aeruginosa cellular invasion41–43. No difference between
LESB65 and ΔpmrB was observed for invasion of Detroit
pharyngeal epithelial cells (Fig. 5b) that express lower levels of
CFTR (Fig. 3c).
Motility in P. aeruginosa is mediated via both type IV pili and
ﬂagella44. Several pili proteins were more abundant in ΔpmrB
than in LESB65 in the proteomic analysis. In motility assays, both
ΔpmrB and pmrB SNP showed enhanced ﬂagella-dependent and
type IV pili-dependent swarming45 relative to LESB65 or pmrB
WT (Fig. 5c, d). No difference in ﬂagella-dependent swimming
or pili-dependent twitching was observed (Supplementary
Fig. 8A–D). Swarming takes place on the sort of viscous or
semisolid surfaces typiﬁed by the mucous of the CF lung and
swarming motility is thought to be linked to the expression of
virulence factors46. Thus, enhanced swarming in ΔpmrB may be
an adaptation to the host environment.
Proteomics comparison of pmrB SNP with pmrB deletion
mutant. Our in vitro data suggested that deletion of pmrB
reproduced the phenotype of the mouse model pmrB SNP isolate.
Direct proteomic comparison of LESB65, pmrB SNP and ΔpmrB
conﬁrmed this, with the two pmrB mutant strains clustering
together, and away from LESB65 in principal component analysis
(Fig. 6). PmrA (p= 2.76 × 10−5) and PmrB (p= 5.74 × 10−10)
were signiﬁcantly less abundant in pmrB SNP relative to LESB65,
as proteins were involved in phenazine biosynthesis (phzG1,
phzM, phzB1, phzA2), LPS modiﬁcation (arnA, arnB, arnD,
arnT, waaG) and antimicrobial resistance (CprA, PA4775). Type
IV pili proteins were enriched in pmrB SNP vs. LESB65 (PilY1,
PilF) (Supplementary Data 2). Peptide counts for Cif and Ivy
100
a
b
c
80
60
40%
 o
f e
ve
n
ts
20
0
100,000
120,000
90,000
60,000
30,000
0
80,000
60,000
40,000
20,000
0
Uninfected LESB65 pmrB WT pmrB SNP ΔpmrB
Uninfected LESB65 pmrB WT pmrB SNP ΔpmrB
100 101
CFTR AF488
CF
TR
 M
FI
CF
TR
 M
FI
102 103 104
ns
***
ns
*
*
****
105
Fig. 3 ΔpmrB downregulates CFTR expression on airway epithelial cells.
a CFTR expression on uninfected (red), LESB65 infected (black) and ΔpmrB
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were below the cut-off threshold for analysis in these experi-
ments, but expression differences were conﬁrmed by qPCR
(Supplementary Table 3).
Mutations in pmrB in clinical P. aeruginosa isolates. Although
loss of pmrB appears to confer phenotypic changes that
facilitate establishment of infection in vivo (Figs. 1, 3, 4, 5), it i-
s also associated with increased susceptibility to antibiotics
(Supplementary Fig. 3, Table 1). It is not clear, therefore, whether
such mutations would be advantageous in clinical P. aeruginosa
infection, where intensive antibiotic therapy is the norm.
Sequencing of pmrB of 13 Liverpool Epidemic Strain (LES) iso-
lates taken from four CF patients attending the Children’s
CF centre in Liverpool between 1995 and 200447 revealed the
presence of SNPs in two isolates from two different individuals.
A SNP in isolate 49,194 resulted in conversion of PmrB arginine
202 to histidine, whilst three SNPs in isolate 49,137 from a
different patient led to isoleucine 73 to leucine, glutamate 82
to lysine, and glutamate 225 to glutamine conversions. Both
isolates had amino acid changes (at position 202 in 49,194
and 225 in 49,137) in proximity to the conserved H-box region
of PmrB. The pmrB SNP isolate from the mouse model that
was used in this study and described previously also had an
amino acid change in the H-box region (L256Q)6. Clinical iso-
lates 49,194 and 49,137 both showed high levels of resistance
to lysozyme and were amongst the most susceptible to
antibiotics of the isolates from each of the two individuals (Fig. 7
and Supplementary Table 4). Furthermore, both 49,194 and
49,137 showed evidence of increased cif and ivy expression rela-
tive to paired isolates from the same patients (Supplementary
Table 5). Considerable variation in both lysozyme and antibiotic
resistance was observed amongst isolates from a single patient,
highlighting the within-patient phenotypic diversity of P. aeru-
ginosa (Fig. 7 and Supplementary Table 4). Thus, pmrBmutations
are evident in clinical P. aeruginosa isolates and are associated
with similar phenotypic traits to those identiﬁed in the isolates
from our mouse model.
Discussion
Based on our observations, we propose a model whereby
pmrB mutants are selected during early infection due to
the advantages they confer in colonisation of the host niche
(summarised in Fig. 8). Furthermore, as part of a genotypically
and phenotypically diverse P. aeruginosa population, such
as exists in the CF lung48–53, pmrB mutation may confer
a population-wide beneﬁt through modulation of the
host environment via CFTR inhibition. Given the
evolutionary trade-offs associated with pmrB mutation,
including enhanced susceptibility to antibiotics, it may be that the
maintenance of population diversity is key during clinical
infections.
Many of our observations have been made using isolates
adapted to the murine lung, which serves as a useful model
for human lung infections but does not fully reproduce the
features of the CF lung environment. We chose isolate LESB65
for these studies due to its ability to establish long-term
infection of the murine respiratory tract6. However, as a clinical
CF isolate, it might be argued that it is already adapted to the
environment of the respiratory tract. However, P. aeruginosa
infection of the CF is characterised by genotypic and phenotypic
diversity48–53, and no single isolate is likely to capture the extent
of this diversity. Different mutations are likely to provide ﬁtness
beneﬁts at different stages of infection, and pmrB mutation
appears most important during early establishment of colonisa-
tion. In established infection, other genotypes may take over or
coexist in a diverse population. We have demonstrated that pmrB
mutations occur amongst clinical isolates (Fig. 8)54 and that they
have the capacity to make signiﬁcant contributions to success of
infection at the population level. Analysis of a larger pool of
clinical isolates from the early stages of infection, to quantify the
prevalence of loss-of-function pmrB mutations, and the impact
on antimicrobial susceptibility, would provide further insight into
this crucial period. Such studies will help determine the extent
to which the phenotypes of lysozyme resistance and environ-
mental modulation, we identify here are selected during infection
in people with CF.
Collectively, these data highlight the range of P. aeruginosa
virulence and regulatory mechanisms linked to the PmrAB
two-component regulatory system. Mutations in pmrB may be
a sentinel early event in adaptation to the host respiratory
tract. The evolutionary trade-off associated with pmrB
mutation, whereby increased in vivo ﬁtness is partially offset by
antibiotic susceptibility, may offer opportunity for intervention
with intensive eradication therapy in early infection. Such an
approach would rely on early detection of infection and our
earlier ﬁndings that the upper respiratory tract acts as an
evolutionary nest for P. aeruginosa suggests that nasal swabbing
could offer a route to earlier diagnosis and treatment in high
risk individuals, including those with CF.
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Methods
Bacterial isolates and gene deletion mutant isolates. LESB65 WT, pmrB WT
and pmrB SNP were used and described in a previous study6. The LESB65 ΔpmrB
mutant was created speciﬁcally for this study. Upstream and downstream regions
of pmrB were ampliﬁed using Q5 high ﬁdelity DNA polymerase (NEB) using
primer sets PmrB1_Xbal 5′-TACTATTCTAGAGGACGACCTGCTGCTCG-3′/
PmrB2_Kpn1 5′AATCCAGGTACCCGGGGGACTCCGGTAGGC-3′–and
PmrB3_Kpn1 5′CCAAATGGTACCTAGCCTGCGCATTGGCCGGG-3′/
PmrB4_EcoRI 5′CCTTGTGAATTCCGGCGAACGCCTGGAGCTA-3′. Restric-
tion sites are underlined. Following digestion with Xbal and Knp1 (upstream
regions) or Knp1 and EcoRI (downstream region), the amplicons were ligated into
the Xbal/EcoRI sites of pEX18Gm “donor” and transformed into Escherichia coli
GT115 (selected on gentamicin 10 mg per L). LESB65 WT and a helper E. coli
GT115 (pRK2013) were grown on nutrient agar containing 25 mg/L trimethoprim
and 25 mg per L kanamycin respectively. P. aeruginosa LESB65 was grown at 42 °C
and E. coli at 30 °C, overnight. 1 ml of overnight culture was centrifuged at 6500 r.p.
m. and resuspended gently in SOB. Recipient, donor, and helper were mixed at a
ratio of 3:1:1 ratio and 150 µl were pipetted onto the surface of a SOB plate. These
were incubated for 20 h at 30 °C. Bacteria were removed from the plate and
reinoculated onto agar plates containing 25 mg per L trimethoprim and 200 mg per
L gentamicin. Colonies were grown overnight and then negatively selected based
on growth on 5% 9 (v/v) LB Sucrose (with trimethoprim and gentamicin) plates.
Colonies were then grown in LB with trimethoprim (25 mg per L) and then plated
to assess for no gentamicin sensitivity. Knockout mutants were conﬁrmed by
Sanger sequencing of the pmrB region (Source Biosciences). PAO1 and
transposon mutants from the Two-Allele library were purchased from the Manoil
lab (University of Washington) and transposon insertion/gene absence conﬁrmed
by PCR (data not shown). Cif and Ivy mutant references are Cif-G08::ISlacZ/hah
and PA3902-F10::ISphoA/hah.
Neutrophil degranulation resistance assays. Mouse bone marrow macrophages
were isolated from mouse femurs and tibias as previously described55. Brieﬂy, a 25-
gauge needle was used to ﬂush cells from bones and ﬁltered through a 100 µm cell
strainer. After washing in cold PBS, cells were separated by histopague 1119/1077
density gradient centrifugation. Purity was conﬁrmed by ﬂow cytometry staining
for Ly6G and CD11b. HL-60 neutrophils (5 × 105 per ml) or mouse bone marrow
macrophages (5 × 105 per ml) were cultured with phorbol myrisate acetate (PMA)
for 4 h to induce degranulation and cell-free culture supernatants were transferred
to 1 × 105 pelleted mid-log LESB65, pmrB WT, pmrB SNP and ΔpmrB. CFU were
determined after 1 h exposure, by serial dilution onto LB agar.
Minimum inhibitory concentration. A broth microdilution method was used to
determine the MIC of various host antimicrobial peptides and antibiotics on the
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P. aeruginosa strains LESB65, pmrB WT, pmrB SNP and ΔpmrB. Following bac-
terial growth on LB agar plates at 37 °C for 18 h, a single colony was inoculated into
5 ml of LB broth and incubated for a further 18 h at 37 °C and 180 r.p.m. A fresh
dilution in LB broth was made by incubating 200 µl of the overnight culture in 5 ml
of fresh LB media. A hundred microliters from the fresh bacterial culture were
incubated in 96 well-plates with 100 µl of 1:2 serially diluted antimicrobial peptide
in LB. After a 24 h static incubation at 37 °C the OD600 was determined to assess
bacterial growth. The antimicrobial peptides used were the cathelicidin anti-
microbial peptide LL37, lysozyme from chicken egg white (Sigma-Aldrich, Gil-
lingham, UK), and β-defensin. The concentration range of the antimicrobial
peptide used in the MIC assays varied between peptides: 0-100 µg per ml for LL37,
0-10 µg per ml for β-defensin and 0-250 µg per ml for lysozyme.
MIC assay in artiﬁcial sputum media. The artiﬁcial sputum media was prepared
as previously described56,57 using DNA from ﬁsh sperm (Sigma-Aldrich), mucin
from porcine stomach (Sigma-Aldrich), the iron-chelator diethylene triamine
pentaacetic acid (Sigma-Aldrich), NaCl (Sigma-Aldrich), KCl (Sigma-Aldrich), egg
yolk emulsion (Sigma-Aldrich) and all essential and non-essential amino acids
(Fisher Scientiﬁc, Loughborough, UK and Sigma-Aldrich). Similarly to the MIC
assay in LB, the bacterial isolates LESB65, pmrB WT, pmrB SNP and ΔpmrB were
grown in LB agar plates at 37 °C for 18 h. Following incubation, a single colony was
inoculated into 5 ml of LB and incubated for 18 h at 37 °C and 180 r.p.m. The
overnight culture was diluted into fresh LB broth to an OD600 of 0.05. A 1:100
dilution of the bacterial solution was done in sterile ASM and 1.8 ml of the solution
was incubated with 200 µl of engineered lysozyme25 or tobramycin (Flynn Pharma
LTD, Hertfordshire, UK) at different concentrations for 24 h at 37 °C and 50 r.p.m.
Following incubation, the ASM bioﬁlm was dissolved using Sputasol (Oxoid,
Basingstoke, UK). The CFU from each bioﬁlm was determined using the Miles and
Misra technique58.
Sequencing analysis. Three P. aeruginosa LESB65 isolates were sequenced using
two Paciﬁc Biosciences RS-II SMRT-cells per isolate (a total of six SMRT-cells)
using P2/C4 chemistry: The parental isolate (LESB65), pmrB SNP, and pmrB WT.
Subreads were assembled using canu v.1.7.11, and single nucleotide polymorphisms
were extracted and annotated using SNIPPY, which takes fake reads generated
from the canu consensus sequence, maps these to a reference sequence (P. aeru-
ginosa LESB58) using bwa-mem2 and extracts SNP using Freebayes3 and SNPEff4.
As Paciﬁc Biosciences sequencing is prone to systematic insertion/deletion errors in
homopolymeric tracts, these were removed from the subsequent analysis. Data are
available under accessions ERS2269679 (http://ddbj.nig.ac.jp/DRASearch/sample?
acc=ERS2269679) (Parent); ERS2269680 (http://ddbj.nig.ac.jp/DRASearch/
sample?acc=ERS2269680) (pmrB SNP) and ERS2269681 (http://ddbj.nig.ac.jp/
DRASearch/sample?acc=ERS2269681) (pmrB WT).
Proteomic analysis. The LESB65, pmrB SNP and ΔpmrB strains were incubated
on LB agar plates for 18 h at 37 °C. A sweep of colonies were inoculated into 5 ml of
LB broth and incubated for a further 18 h at 37 °C and 180 r.p.m. A fresh dilution
in LB broth was made by incubating 1.2 ml of the overnight culture into 28.8 ml of
fresh LB media. The bacteria were incubated at 37 °C and 180 r.p.m. to an OD600
between 0.5 and 0.6 and pelleted down at 4500 r.p.m. for 12 min. The pellet was
washed once in phosphate buffered saline and stored at −80 °C until processing for
proteomic analysis. Five replicates per condition were used. Bacterial cell pellets
were lysed by sonication 1% (w/v) SDC in 50 mM ammonium bicarbonate.
Samples were heated at 80 °C for 15 min before centrifugation at 12,000×g to pellet
debris. The supernatant was retained, and proteins reduced with 3 mM DTT
(Sigma) at 60 °C for 10 min, cooled, then alkylated with 9 mM iodoacetamide
(Sigma) at RT for 30 min in the dark; all steps were performed with intermittent
vortex-mixing. Proteomic-grade trypsin (Sigma) was added at a protein:trypsin
ratio of 50:1 and incubated at 37 °C overnight. SDC was removed by adding TFA to
a ﬁnal concentration of 0.5% (v/v). Peptide samples were centrifuged at 12,000×g
for 30 min to remove precipitated SDC.
NanoLC MS ESI MS/MS analysis. Peptides were analysed by on-line nanoﬂow
LC using the Ultimate 3000 nano system (Dionex/Thermo Fisher Scientiﬁc).
Samples were loaded onto a trap column (Acclaim PepMap 100, 2 cm × 75 μm
inner diameter, C18, 3 μm, 100 Å) at 5 μl min−1 with an aqueous solution con-
taining 0.1% (v/v) TFA and 2% (v/v) acetonitrile. After 3 min, the trap column was
set in-line an analytical column (Easy-Spray PepMap® RSLC 50 cm × 75 μm inner
diameter, C18, 2 μm, 100 Å) fused to a silica nano-electrospray emitter (Dionex).
The column was operated at a constant temperature of 35 °C and the LC system
coupled to a Q-Exactive HF mass spectrometer (Thermo Fisher Scientiﬁc).
Chromatography was performed with a buffer system consisting of 0.1% formic
acid (buffer A) and 80% acetonitrile in 0.1% formic acid (buffer B). The peptides
were separated by a linear gradient of 3.8–50% buffer B over 90 min at a ﬂow rate
of 300 nl per min. The Q-Exactive HF was operated in data-dependent mode with
survey scans acquired at a resolution of 60,000. Up to the top 10 most abundant
isotope patterns with charge states +2 to +5 from the survey scan were selected
with an isolation window of 2.0Th and fragmented by higher energy collisional
dissociation with normalised collision energies of 30. The maximum ion injection
times for the survey scan and the MS/MS scans were 100 and 45 ms, respectively,
and the ion target value was set to 3E6 for survey scans and 1E5 for the MS/MS
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scans. MS/MS events were acquired at a resolution of 30,000. Repetitive sequencing
of peptides was minimised through dynamic exclusion of the sequenced peptides
for 20 s.
Protein identiﬁcation and quantiﬁcation. Thermo RAW ﬁles were imported into
Progenesis QI for proteomics (version 4.1, Nonlinear Dynamics). Runs were time
aligned using default settings and using an auto selected run as reference. Peaks
were picked by the software using default settings and ﬁltered to include only peaks
with a charge state between +2 and +7. Spectral data were converted into.mgf ﬁles
with Progenesis QI for proteomics and exported for peptide identiﬁcation using the
Mascot (version 2.3.02, Matrix Science) search engine. Tandem MS data were
searched against translated ORFs from Pseudomonas aeruginosa strain PAO1
(Uniprot reference proteome, UP000002438, December 2016) and a contaminant
database (cRAP, GPMDB, 2012) (combined 5733 sequences; 1,909,703 residues).
The search parameters were as follows: precursor mass tolerance was set to 10 p.p.
m. and fragment mass tolerance was set as 0.05 Da. Two missed tryptic cleavages
were permitted. Carbamidomethylation (cysteine) was set as a ﬁxed modiﬁcation
and oxidation (methionine) set as variable modiﬁcation. Mascot search results were
further validated using the machine learning algorithm Percolator embedded
within Mascot. The Mascot decoy database function was utilised and the false
discovery rate was <1%, while individual percolator ion scores >13 indicated
identity or extensive homology (p < 0.05). Mascot search results were imported into
Progenesis QI for proteomics as XML ﬁles. Peptide intensities were normalised
against the reference run by Progenesis QI for proteomics and these intensities
were used to highlight relative differences in protein expression between sample
groups. Only proteins with 2 or more identiﬁed peptides were included in the
dataset. Statistical analysis (ANOVA) of the data was performed using Progenesis
QI for proteomics to identify signiﬁcantly (p < 0.05, q ≤ 0.05, relative fold change
≥2) differentially expressed proteins. PCA plots were created using ClustVis using
proteins with 2 or greater identiﬁed peptides, and q < 0.05. Unit variance scaling
was applied to rows; SVD with imputation was used to calculate principal
components.
MALDI-MS of Lipid A modiﬁcations. Cultures were initially prepared as
described for the proteomic analysis. Bacteria were aliquoted (1 ml) into a 1.5 ml
microtube prior to heat-inactivation for 1 h at 90 °C. The heat-inactivated bacteria
were washed three times with 0.5 ml of double distilled water and centrifuged at
9000×g for 5 min and suspended in double distilled water at a ﬁnal concentration
of about 104 to 105 bacteria per μl. Four biological replicates (each with 4 technical
replicates) were performed on the LESB65 WT and the ΔpmrB knockout mutant.
Suspensions of 104 to 105 bacteria per µL were stored at −80 °C until required. 0.5
µL of bacterial suspension was spotted onto a stainless steel MALDI plate, 0.5 µL of
the matrix, 2,5-dihydrobenzoic acid (DHB) made to a ﬁnal concertation of 10 mg/
mL in a 90:10 chloroform/methanol solution, was spotted on top of the bacterial
suspension. MALDI q-TOF analysis were acquired using a Synapt G2-Si (Waters,
UK). Negative ion data were recorded in resolution mode, with a mass range of m/z
1000–2200. Data was acquired for 180 s per sample with a scan rate of 1 scan
per second and a laser repetition rate of 500 Hz. Average Spectra per acquisition
were produced using MassLynx V4.1 (Waters, UK) and processed using the
automatic peak detection with background subtraction. Peak intensities were
normalised to the average total ion current of the acquisition. A peak was detected
at m/z meas 1615.9873 corresponds to hexa-acyl Lipid A (m/z calc 1615.9879,
Δppm −0.37). Another peak was detected at m/z meas 1445.8531 corresponds to
penta-acyl Lipid A (m/z calc 1445.8572, Δppm −2.8).
Pyocyanin production. Pyocyanin assays were carried out on culture supernatants
during growth in LB as described previously47. The amount of pyocyanin in culture
supernatants was quantiﬁed by measuring the OD695 value. For overnight cultures,
it was important to shake the culture vigorously before obtaining the supernatant.
This is to ensure that all of the pyocyanin present is in the oxidised form. We used
a simple broth test to identify strains with increased blue/green pigment produc-
tion compared to strain PAO1. Following overnight growth in universals con-
taining 5 ml Luria broth, with shaking at 200 r.p.m. Full pyocyanin production
assays were carried out using 250 ml ﬂasks containing 50 ml LB and absorbance at
695 nm for supernatants and 600 nm for cell cultures.
CFTR expression in airway epithelial cells. A549 alveolar epithelial cells (ATCC
CCL-185) and Detroit 562 pharyngeal cells (ATCC CCL-138) were obtained from
the American Type Culture Collection (Manassas, USA) and epithelial phenotype
conﬁrmed by microscopy and ﬂow cytometry. Cells were conﬁrmed mycoplasma-
free before performing experiments. Airway cells, at 105 per well, were seeded in 12
well plates and grown until the monolayer of cells were conﬂuent, then infected
with bacteria (CFU 104) and incubated overnight at 37 °C. Cells were washed once
with PBS removed with a cell scraper before four wells from each treatment group
were pooled and CFU counts performed. A549 cells were washed and then incu-
bated with anti-CD16/32 (Human TruStain FcX, BioLegend, cat. 422301) in PBS
1% (w/v) BSA for 30 min at room temperature. Cells were washed and then ﬁxed
and permeabilised (BD Biosciences) before staining with anti-CFTR AF488
(AbCam, cat. ab2784) in permeabilisation buffer (BD Bioscience) for 30 min at
room temperature. Flow cytometry was performed using the BD FACSCelesta
(BioSciences, Warrington, United Kingdom) and data analysed using Flow Jo v8.3
(Tree Star Inc, USA). Flow cytometry experiments were performed twice with two-
three biological replicates per assay.
Mouse infections. All mouse infection work was performed at the University of
Liverpool with prior approval by the UK Home Ofﬁce and the University of
Liverpool Ethics Committee. The female BALB/c mice of 6-8 week old (Charles
River, UK) were used for infection experiments and housed in individually ven-
tilated cages for one week to acclimatise prior to infection. Sample size determi-
nation was performed as previously described, informed from previous work
comparing P. aeruginosa infection density in mice6. Mice were randomly assigned
to a cage (experimental group) on arrival at the unit by staff with no role in study
design. 2 × 106 colony forming units of PAO1 or PAO1 transposon mutants were
instilled into the nares of mice that had been lightly anaesthetised with a mixture of
isoﬂurane and oxygen. Cage labels were reversed to ensure researchers were
blinded to experimental groups. Mice were monitored for signs of disease and
culled at pre-determined time points. Nasopharyngeal tissue and lungs were
removed post-mortem and homogenised in 3 ml PBS using an IKA T10 handheld
tissue homogeniser (IKA, USA), before serial dilution onto Pseudomonas selective
agar (Oxoid, UK) for enumeration of infectious burden. Following enumeration,
researchers were unblinded. No animals were excluded from analysis.
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Adhesion and invasion of airway epithelial cells. Differential adhesion and
invasion assay performed as previously described59,60. Brieﬂy, A549 alveolar epi-
thelial cells (ATCC CCL-185) or Detroit 562 pharyngeal cells (ATCC CCL-138)
(both at 105 per well) were seeded in 2 × 24 well plates and grown until conﬂuent
then infected with bacteria (CFU 104) and incubated for two hours. Cells were
washed ﬁve times with PBS to remove non-adherent bacteria and for invasion
assay, samples were incubated for a further two hours in media with 600 mg per ml
gentamicin to kill extracellular and adherent bacteria (adhesion control was per-
formed without gentamicin). The cells were washed three times with PBS and 100
µl trypsin added to remove cells from the plate (incubated for 10 min), then cells
lysed with 100 µl 0.05% (v/v) Triton x100 in incubator for 10 min. Samples were
plated on LB agar in 10-fold dilutions up to 10−6 using the Miles & Misra tech-
nique58 and incubated at 37 °C for 48 h, at which point bacterial CFU were
counted. Experimental conditions were performed in duplicate and repeated ﬁve
times. Adhesion CFU per ml was calculated by removing invasion counts from
invasion plus adhesion counts.
Bacterial motility assays. Swim and swarm petri dish plates were inoculated on
the surface as described previously61,62, then incubated for 14 and 16 h, respec-
tively, at 37 °C. Swim plates were ﬁrst loosely wrapped in cling ﬁlm to prevent
dehydration, and incubated without inversion. The visible diameter of bacterial
growth was measured at the widest point after incubation. Twitching motility was
determined by subsurface stab assay of a colony of bacteria deep into LB agar until
it touched the agar-dish interface63, then motility zone measured after incubation
for 24 h at 37 °C. To visualise the twitching motility diameter, agar was removed
with tweezers and plates stained with 10 ml 0.25% (w/v) crystal violet for 30 min
before rinsing with water. An isolate with diameter < 10 mm at widest point was
considered twitching motility impaired, with experiments repeated ﬁve times.
PCR ampliﬁcation and sequencing of pmrB. PCR ampliﬁcation was carried out as
described previously64. Ampliﬁcation of the pmrB region was carried out using the
oligonucleotide primer sets pmrBF (5′- CCTACCCCTCTCGCTGAAG-3′)/pmrBR
(5′-GATGTTCATCCGGGTCTCCT-3′). PCR amplicons were puriﬁed using
Qiaquick PCR puriﬁcation columns (Qiagen) and sequenced by Source Bioscience
using the same oligonucleotide primers employed in the PCR ampliﬁcation.
Quantitative real-time PCR (qPCR) and analysis. qPCR was performed using
the Rotor-Gene Q cycler (Qiagen) as described previously6. Speciﬁc forward and
reverse primers were used to target cif (cif_F-TGGCACTTCAGTTTCTTCGC and
cif_R-TGTTGCTGGAATGGGACTTG primerS) and ivy (ivy_F-GAGTATCCAG
ACTGCTCTCCC and ivy_R-TGGGGTTTGCAACTGTTGG primers). Each qPCR
was performed with three biological replicates and in duplicate on each run. A
standard curve of known copy number was performed in each run. Obtained data
were analysed using the Rotor-Gene Q series software (Qiagen). Relative expression
levels of genes cif and ivy were calculated using the two-standard curve method.
Genes proC and rpoD, encoding the pyrroline-5-carbocylate reductase and sigma
factor RpoD, respectively, were used as reference genes. A standard curve was
constructed for each target and reference genes.
Statistical analysis. Statistical analysis was performed in GraphPad Prism V 6.0
(GraphPad Software, La Jolla, USA) and data were tested for normality and to
deﬁne the variance of each group tested. All multi-parameter analyses included
corrections for multiple comparisons and data are presented as mean ± standard
deviation (SD) unless otherwise stated. For MIC determination, median values are
stated and odd numbers of replicates performed to avoid derived values.
Data availability. PacBio sequence data are available from DDBJ sequence read
archive under accessions ERS2269679 (LESB65), ERS2269680 (pmrB SNP) and
ERS2269681 (pmrB WT). The mass spectrometry proteomics data have been
deposited to the ProteomeXchange Consortium via the PRIDE65 partner repository
with the dataset identiﬁers PXD009705 and 10.6019/PXD009705. All other data
supporting the ﬁndings of the study are available in this article and its Supple-
mentary Information ﬁles, or from the corresponding authors on request.
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